New antibody targets FGFR1 to fight metastatic cancers

NCT ID NCT07292168

Recruiting now Disease control Sponsor: Kidney Cancer Research Bureau Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called OM-RCA-01, an antibody that blocks a protein called FGFR1 found on some cancer cells. About 58 adults with metastatic kidney, lung, prostate, breast, or head and neck cancers that express FGFR1 will receive the drug by IV every two weeks. The goal is to find a safe dose and see if it can slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OM-RCA-01 (a monoclonal antibody targeting FGFR1)
What this could lead to: If it works, this could provide a new treatment option for several metastatic cancers that express FGFR1, potentially slowing tumor growth.
What could go wrong: This is an early-phase trial with only 58 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Apert syndrome breast cancer breast neoplasm castration-resistant prostate carcinoma head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma kidney cancer lung neoplasm metastatic prostate carcinoma Neoplasm Metastasis non-small cell lung carcinoma nonpapillary renal cell carcinoma prostate cancer renal cell carcinoma salivary gland cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER, METASTATIC HEAD NECK CANCER NON-SMALL CELL LUNG CANCER METASTATIC PROSTATE CANCER METASTATIC RENAL CELL CARCINOMA, METASTATIC

Contacts and locations

Locations

A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center
RECRUITING

Krasnoyarsk, Russia
Hadassah Medical
RECRUITING

Moscow, Russia
I.P. Pavlov First Saint Petersburg State Medical University
RECRUITING

Saint Petersburg, Russia
Republican Clinical Oncology Dispensary
RECRUITING

Ufa, Russia
Republican Dispensary of Tatarstan
ACTIVE_NOT_RECRUITING

Kazan', Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.